Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice

Autor(es):Mostrar menos -

Pereira Ribeiro, Jefferson Bruno ^[1] ; Miranda-Vilela, Ana Luisa ^{[2, 3]} ; Graziani, Daniel ^[1] ; de Aguiar Gomes, Misleia Rodrigues ^[4] ; Santarem Amorim, Ana Angelica ^[1] ; Garcia, Rafaela Debastiani ^[1] ; de Souza Filho, Jose ^[2] ; Tedesco, Antonio Claudio ^[5] ; Primo, Fernando Lucas ^[5] ; Moreira, Jonathan Rosa ^[6] ; Lima, Alexandre Vasconcelos ^[7] ; Ribeiro Sampaio, Raimunda Nonata ^[1]

Afiliação do(s) autor(es)

^[1] Univ Brasilia, Fac Med, Lab Dermatomicol, Campus Univ Darcy Ribeiro, BR-70910900 Brasilia, DF - Brazil

^[2] Univ Brasilia, Inst Ciencias Biol, Dept Genet & Morfol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF - Brazil

^[3] Fac Integradas Uniao Educ Planalto Cent Faciplac, Curso Med, Campus Gama, BR-72460000 Gama, DF - Brazil

^[4] Univ Brasilia, Lab Farmacognosia, Fac Med, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF - Brazil

^[5] Univ Sao Paulo, Dept Quim, Lab Fotobiol & Fotomed, Ctr Nanotecnol & Engn Tecidual, Fac Filosofia Cien, BR-14040901 Ribeirao Preto, SP - Brazil

^[6] NDC, Fac Projecao, BR-72115700 Taguatinga, DF - Brazil

^[7] Inst Brasileiro Seguranca Transito, SRTVS Quadra 701 Bloco 3, Edificio Palacio Radio 1, BR-70340901 Brasilia, DF - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Photodiagnosis and Photodynamic Therapy; v. 13, p. 282-290, MAR 2016.
• Citações Web of Science: 11

Resumo

Background: The shortage of drugs is a concern and has become the object of studies to discover effective alternatives for cutaneous leishmaniasis (CL) treatment. A topical formulation has been sought due to its low toxicity. Development of alternative therapies, such as multimodal ones, is important in confronting drug resistance. This study aims to compare the in vivo efficacy of topical photodynamic therapy (PDT) using liposomal chloroaluminium phthalocyanine (AlClPC) in the treatment of CL, isolated and associated with systemic therapy with miltefosine. Methods: Five groups were adopted, each one with six isogenic adult female mice C57BL/6: (1) Negative Control non-infected and non-treated; (2) Positive Control (PBS)-infected and non-treated; (3) Miltefosine-infected and treated with oral miltefosine 200 mg/kg/day; (4) Infected and treated with PDT with topical AlClPC (500 mu l) on alternate days; (5) Oral Miltefosine 200 mg/kg/day and PDT with topical AlClPC (5004) on alternate days. Therapeutic schemes lasted 20 days. Infection was confirmed by culture in Nove-McNeal-Nicolle medium (NNN) of lymph collected from the animal paw, and animals were evaluated by paw measurement and parasitological criteria. Results: Miltefosine associated with PDT with AlClPC promoted a significant reduction in parasite number and viability when compared to the other infected groups, also returning the paw diameter to a size similar to the negative control group after 20 days of treatment. Conclusions: Association of miltefosine with PDT mediated by topical AlClPC represents hopes for CL treatment, an increasing dermatological disease in some countries. (C) 2015 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 08/53719-4 - Utilização de nanocarreadores contendo fármacos fotossensíveis e outros ativos derivados de fatores de crescimento aplicados a processos fotodinâmicos nas áreas da saúde
• Beneficiário: Antonio Claudio Tedesco
• Modalidade de apoio: Auxílio à Pesquisa - Temático